Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).
| dc.contributor.author | Paz-Ares, Luis | |
| dc.contributor.author | Perol, Maurice | |
| dc.contributor.author | Ciuleanu, Tudor-Eliade | |
| dc.contributor.author | Kowalyszyn, Ruben Dario | |
| dc.contributor.author | Reck, Martin | |
| dc.contributor.author | Lewanski, Conrad R. | |
| dc.contributor.author | Syrigos, Konstantinos N. | |
| dc.contributor.author | Arrieta, Oscar | |
| dc.contributor.author | Prabhash, Kumar | |
| dc.contributor.author | Park, Keunchil | |
| dc.contributor.author | Pikiel, Joanna | |
| dc.contributor.author | Goeksel, Tuncay | |
| dc.contributor.author | Lee, Pablo Sang | |
| dc.contributor.author | Zimmerman, Annamaria | |
| dc.contributor.author | Treat, Joseph | |
| dc.contributor.author | Ferry, David | |
| dc.contributor.author | Melemed, Allen S. | |
| dc.contributor.author | Carter, Gebra Cuyun | |
| dc.contributor.author | Alexandris, Ekaterine | |
| dc.contributor.author | Garon, Edward B. | |
| dc.date.accessioned | 2019-10-27T20:25:28Z | |
| dc.date.available | 2019-10-27T20:25:28Z | |
| dc.date.issued | 2015 | |
| dc.department | Ege Üniversitesi | en_US |
| dc.description | Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL | en_US |
| dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.issn | 1527-7755 | |
| dc.identifier.issue | 15 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11454/42234 | |
| dc.identifier.volume | 33 | en_US |
| dc.identifier.wos | WOS:000358036901767 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Amer Soc Clinical Oncology | en_US |
| dc.relation.ispartof | Journal of Clinical Oncology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). | en_US |
| dc.type | Conference Object | en_US |
